– Agreement on marketing and R&D cooperation enhancing market position short- and long-term
Prostatype Genomics AB (“Prostatype Genomics”) has signed a cooperation agreement with Proteomedix AG (“Proteomedix”), a Zurich based science-driven company that has an approved product in the field of prostate cancer. The product is complementary to Prostatype®, the gene based prognostic tool developed and marketed by Prostatype Genomics.
Used in different stages of the clinical process of prostate cancer, Prostatype® and the complementary product this will offer unique decision support for patients and physicians.
The marketing agreement is non-exclusive and covers many of Prostatype Genomics’ prioritized markets, such as Germany, Italy, Sweden, Switzerland and the UK.
As an important future-looking part of the cooperation, Prostatype Genomics and Proteomedix will establish a Research & Development cooperation, working to further enhance the clinical value by looking into synergies between the tests. The collaboration will strengthen Prostatype on the commercial as well as on the R&D-side. The expected activities within the framework of the cooperation include, among other things, execution of a pilot study as well as clinical validation studies, several new distribution agreements in the EMEA and quicker market entries in EMEA and US by expansion of commercial organisations.
Fredrik, Persson, CEO of Prostatype Genomics, comments: “Working together with our new partner is the definition of a win-win! We are both growing our market footprints, and the wider offering will make us more attractive for payers, labs and physicians. Looking beyond the sales and marketing cooperation, I am very excited about starting up the R&D cooperation. Combining these two leading technologies could result in something completely new. To maximize the benefits of this exciting cooperation we will look into the possibilities to raise additional funding shortly”.
This disclosure contains information that Prostatype Genomics AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 26-08-2021 21:15 CET.